Full Agenda Announced for CBI's Commercialization and Market Access Congress (CMAC 2010)

WOBURN, Mass., Sept. 30 /PRNewswire/ -- The Center for Business Intelligence (CBI) recently announced the full agenda for their life sciences Commercialization and Market Access Congress (CMAC 2010). CBI, a renowned leader in the commercialization arena, has combined four of their most respected events - Product Launch, Product Pricing, Early-Stage Commercialization and Specialty Drug Commercialization - into one comprehensive agenda with extensive coverage of the evolving dynamics impacting market access and commercialization. The Congress takes place December 8-9, 2010 in Orlando, FL.

CMAC 2010 combines both a strategic view of current events impacting commercialization with targeted breakouts and tracks, addressing models for commercialization that respond to the new economic landscape while accounting for the changing relationship between patients, physicians and payers. A keynote panel discussion on "Changes in the Market Access Landscape" will be a highlight at this timely event.

CMAC's speaker faculty includes more than 30 of the country's leading experts from the most innovative biotechnology and medical device companies to the most established pharmaceutical companies including Abbott, AstraZeneca, Bayer HealthCare Pharmaceuticals, Cephalon, Daiichi Sankyo, Endo Pharmaceuticals, Medtronic, Mannkind Corporation, Merck, Pfizer, Schering-Plough, Shire, Talecris Biotherapeutics and many more.  

CMAC 2010 is the industry's only opportunity to participate in an executive-level exchange addressing the overarching product development and launch environment, as well as tactical approaches for pricing, reimbursement, product launch, commercial strategy, branding, managed care and HEOR. For more information on the conference or to view the entire agenda, please visit http://www.cmac2010.com.  

About CBI:

A subsidiary of Advanstar Communications, The Center for Business Intelligence (CBI) is dedicated to developing market-driven, unbiased conferences in the pharmaceutical, biotechnology and medical device industries. CBI's conferences provide a unique platform for concrete, real-life examples that can be applied to any organization immediately, significantly impacting both costs and revenue. For more information, please visit http://www.cbinet.com.  

For additional information or media inquiries, please contact: Emily Forest, Marketing Manager, at 339-298-2156.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE Center for Business Intelligence

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.